Smoking cessation is of current topical interest due to the significant negative health and economic impact in many countries. This study aimed to develop buccal films and wafers comprising HPMC and sodium alginate (SA) for potential use in nicotine replacement therapy via the buccal mucosa, as a cheap but effective alternative to currently used nicotine patch and chewing gum. The formulations were characterised using texture analyser (tensile and hardness, mucoadhesion), scanning electron microscopy, x-ray diffractometry, attenuated total reflection -Fourier transform infrared (ATR-FTIR), differential scanning calorimetry (DSC) and swelling capacity. Drug loaded films and wafers were characterised for content uniformity (HPLC) whilst the drug loaded wafers only were further characterised for in vitro drug dissolution. SA modified and improved the functional properties of HPMC at optimum ratio of HPMC: SA of 1.25 : 0.75. Generally, both films and wafers (blank and drug loaded) were amorphous in nature which impacted on swelling and mucoadhesive performance.
Introduction
The buccal mucosa has become a very attractive route of drug delivery especially for drugs with low bioavailability, poor gastrointestinal stability and susceptibility to first pass metabolism including proteins and peptides [1] by delivering the drug directly into the bloodstream. Although the parental route offers a similar solution, it can be inconvenient to administer due to the pain associated with piercing the skin and requires a trained personnel to perform the task [2, 3] . The transdermal route can also allow the delivery of drugs directly into the bloodstream and has been used in commercial nicotine replacement therapy (NRT) in the form of transdermal patches. Transdermal patches, however, take longer time to achieve a smoker's saturation peak [4] which result in non-compliance.
Nicotine (NIC) is the major component of tobacco used in cigarettes. It is a volatile, alkaline liquid and colourless in nature, highly soluble in both water and other organic solvents with two well separated pKa values (3.04 and 7.84) resulting in different charge species depending on the medium pH. Both charged species can be readily absorbed across the skin and mucosal surfaces [5] .
The physiological and psychomotor symptoms associated with smoking cessation, such as irritability, sleepiness, sleeplessness, unsteadiness, regular coughing, mouth blisters, constipation, chest stiffness and continuous cigarette craving, have been managed using various NRTs. NIC cannot be developed as an oral pill because of its susceptibility to first pass metabolism in the liver, which can retard bioavailability [6, 7] . As a result, different drug delivery strategies have been explored for NRT to increase NIC absorption. These include transdermal patches, chewing gums, lozenges, mouth sprays and nasal spray. These products have been licensed in several countries including UK and Canada to help reduce withdrawal symptoms in the temporary abstinence periods that can usually arise in places where smoking is prohibited e.g. in airplanes, trains or hospitals [8] .
Films and wafers have extensively been investigated as buccal drug delivery systems.
Films are usually prepared by solvent evaporation method [9, 10] while wafers are prepared by a sublimation process known as freeze-drying [11] . There has been research reported on the delivery of NIC via the buccal route using films [12] [13] [14] . Pongjanyakul and Suksri reported the use of SA and magnesium aluminium silicate (MAS) clay films in the buccal mucosal delivery of NIC and demonstrated a promising use of NIC loaded SA-MAS films as mucosal delivery systems [15] . On the other hand, wafers have been employed as wound healing [16] and buccal [18] drug delivery systems. They can therefore be employed in the delivery of NIC, including composite systems combining two or more polymers [16, 17] as demonstrated by Pawar and co-workers [18, 19] who reported the use of composite polymeric wafers combining polyox with either carrageenan or sodium alginate in the development of wafers for controlled delivery of drugs to chronic wound sites [18, 19] .
Films and wafers can possess adhesive properties when formulated with mucoadhesive polymers such as HPMC and sodium alginate (SA). The properties of mucoadhesive polymers such as surface charge and solubility play a vital role in their ability to adhere to mucosal surfaces. Charged polymers such as SA demonstrate higher adhesion than non-ionic polymers (e.g. HPMC), because of their ability to form a strong electrostatic interaction with the charged surface of mucin [20] . The use of composite polymeric systems can be adopted to enhance the functional properties of a polymeric dosage form. HPMC is very effective in designing controlled drug delivery systems while SA can be used to enhance the mucoadhesion of a given polymeric dosage form. Further, the anionic nature of SA provides a potential means of interaction of the amine groups of NIC with the carboxylic acid side chains of SA, which could improve mucoadhesion and provide further control of drug release. [5, 24] .
Functional properties such as tensile (films), hardness (wafer), hydration, adhesion, and drug release are important characteristics of a buccal formulation that can influence its performance. For example, elasticity, flexibility and softness are essential properties to be considered in film formulation as a result of stress from mouth motions which the film needs to be able to withstand [21] .
In this study, we report on the formulation development and comparison of solvent evaporated films and freeze-dried wafers combining HPMC and SA as mucoadhesive systems for potential NRT via the buccal mucosa. The formulations have been characterised using texture analysis, scanning electron microscopy, X-ray diffraction (XRD), attenuated total reflection -Fourier transform infrared (ATR-FTIR) spectroscopy differential scanning calorimetry (DSC) and high-performance liquid chromatography (HPLC) for mechanical/hardness, surface/internal morphology, crystallinity, chemical interactions, thermal, drug content/release properties respectively. The swelling profiles were also determined by calculating the swelling index for hydration and water holding capacity. The characterisation data was used to compare the properties of different HPMC-SA composite films and wafers as well as compare HPMC-SA films and wafers. The selected optimised formulation (wafer) was then further characterised for drug dissolution behaviour.
Experimental

Materials
The materials used in this experiment included; HPMC (Methocel K100 premium LV) obtained as a gift from Colorcon Limited (Dartford, UK). Sodium hydroxide, potassium dihydrogen phosphate and gelatine were all purchased from Fluka Analytical (Buchs, Switzerland); Nicotine (liquid form), sodium alginate, and mucin from porcine stomach were obtained from Sigma-Aldrich (Dorset, UK). Sodium acetate, trimethylamine and glycerol were all purchased from Fisher Scientific (Loughborough, UK).
Preparation of composite films
Blank (BK) viscous polymeric solutions were prepared by dissolving HPMC, sodium alginate (SA) and glycerol (GLY) in 100ml of distilled water at 25°C. The resulting polymeric solutions were left to stand overnight to remove all air bubbles, 30g was poured into a Petri dish (90mm diameter) and dried in an oven at 30°C for 18-20 hrs. Drug loaded (DL) films were prepared as above with the addition of NIC to the polymeric solutions before drying in the oven. The concentrations of polymers, plasticizer and drug used in each viscous polymeric solution have been summarised in Table 1a .
Preparation of composite wafers
Viscous polymeric solutions for BK and DL wafers were prepared in similar manner as for the films but without using GLY. The polymeric solutions (1g) were poured into each well of a 24 well plate (diameter 15.5mm). The concentrations of polymers and drug present in each polymeric solution are summarised in Table 1b . The freeze-dried wafers were prepared using an automated lyophilisation cycle on a Virtis Advantage XL 70 freeze-dryer (Biopharma process systems, Winchester, UK). The well plates containing the polymeric solutions were loaded onto the shelves of the freeze-dryer and programmed for freezing, primary drying and secondary drying steps. The freezing step involved cooling the sample from room temperature to 5°C (40 mins), 5°C to -10°C (40 mins), and then from -10°C to -55°C (120 mins). An annealing step was incorporated into the freezing cycle in other to improve pore size distribution by increasing the temperature from -55°C to -35°C (2 hrs) and then cooling back down to -55°C (3 hrs). Additional freezing was performed to ensure uniformity by freezing at -55°C (1 hr) with a condenser temperature of -55°C and pressure of 200mTorr.
The primary drying occurred under high pressure of 50mTorr, with temperature raised from -55°C to -20°C (8 hrs) and further increased from -20°C to -15°C ° (10 hrs). Secondary drying occurred at the same pressure as primary drying but increasing the temperature from -15°C to 25°C (12 hrs 30 mins).
Texture (TA) analysis
Tensile properties of films
The tensile properties of the films were analysed using a texture analyser (HD plus, Stable Micro System, Surrey, UK) equipped with a 5 kg load cell. Prior to obtaining tensile data, the BK and DL films were cut into dumb-bell shaped strips and the thickness of films was measured using a micrometre screw gauge. The films were fixed in between two tensile grips of the TA instrument and then stretched at a test speed of 2mm/sec till breaking point. The elongation at break (%), tensile strength and elastic modulus was determined using equations 1, 2 and 3 respectively (n=3) [22] .
(1)
Mechanical properties of wafers (hardness)
The resistance to compressive deformation (hardness) of the freeze dried wafers was determined using a texture analyser (HD plus, Stable Micro System, Surrey, UK) equipped with a 5 kg load cell. The BK and DL wafers were compressed on 5 different locations of each wafer (n = 3), using a 2mm cylinder stainless steel probe to a depth of 2 mm at a speed of 1mm/sec with the instrument in compression mode.
Scanning electron microscopy (SEM) analysis
The surface morphology of both BK and DL films and wafers were analysed using a Hitachi SU8030 (Hitachi High-Technologies, Krefeld, Germany) scanning electron microscope.
Films and wafers were cut into small strips and placed on Agar Scientific G301 aluminium pin-type stubs, using Agar Scientific G3347N double-sided adhesive carbon tape. The films were chromium coated, while wafers were gold coated for clearer pore image using a Sputter
Coater (Edwards 188 Sputter Coater S1508). Films were analysed at 2.0kV accelerating voltage while wafers were analysed at 5.0kV accelerating voltage.
Wafer pore analysis
Wafer pore analysis was used to evaluate the porosity of HPMC-SA wafer structure. The wafers were initially weighed and then immersed in 5ml of ethanol in a glass vial and was left to stand for 10 mins. The vials with ethanol and wafers were degassed to remove air bubbles trapped inside the wafers for 10 mins. After degassing, the wafers were carefully removed from the solvent, wiped to remove excess solvent, and immediately weighed to avoid loss of ethanol due to its volatility.
The percentage porosity of wafers was calculated using equation 4 below: 
X-ray diffraction (XRD) analysis
The physical (crystalline/amorphous) form of both BK and DL films and wafers was investigated using a D8 Advantage X-ray diffractometer. Films were cut into small pieces whilst wafers were compressed using two clean cover glasses, placed on the holder and mounted onto the sample cell. For pure starting materials, mylar was used to hold the powders before placing on the sample cell. The samples were analysed in transmission mode at a diffraction angle ranging from 5° to 50° 2θ, step size 0.04°, and scan speed of 0.4s/step.
Attenuated total reflection Fourier transform infrared spectroscopy (ATR-FTIR) analysis
ATR-FTIR spectra were obtained from a Perkin Elmer Spectrum instrument which was equipped with a diamond universal ATR-unit. The composite films and wafers were cut into strips, placed on the ATR diamond crystal and force applied using a pressure clamp to allow adequate contact between the sample and diamond crystal. Pure solid samples (i.e. HPMC and SA) were also examined in a similar way as the films and wafers. For NIC, there was no force applied as the liquid could form intimate contact with the diamond crystal without any applied force. The resolutions of the samples were recorded at 4 cm -1 within the range of 450-4000 cm -1 . Background spectra were subtracted in other to obtain a reliable absorbance of each sample.
Differential scanning calorimetry (DSC) analysis
A DSC Mettler Toledo instrument was used to thermally analyse pure samples as well as BK and DL films and wafers. Films and wafers were weighed (between 1-3mg), placed in Tzero pans and covered with Tzero hermetic lids. The samples were heated from -50°C to 250°C at the rate of 10°C/min under constant purge of nitrogen.
Swelling studies
The swelling capacities of both BK and DL films and wafers were determined by immersing each formulation into 5ml of phosphate buffer (pH 6.8). The percentage swelling index was investigated by recording change in weight at time intervals of 2 mins up to 30 mins. For every time point, the medium was carefully removed to obtain an accurate weight of the sample and replaced with fresh medium. Three replicates were performed for each sample and swelling index (%) was calculated using equation 5 [23] .
Where Wd = dry weight of polymeric film / wafer. Ws = weight of film/wafer after swelling.
Mucoadhesion studies
Adhesion test was performed on BK and DL films and wafers using a TA. HD plus Texture Analyser (Stable micro systems, Surry, UK) in tensile mode and fitted with a 5kg load cell.
Films were cut considering the mathematical area of wafers (a circle with diameter = 15.5mm). The films and wafers were attached to an adhesive probe (75mm diameter) of the TA instrument using a double-sided adhesive tape. Gelatine gel (6.67% (w/v)) was prepared by dissolving gelatine in water at 70°C, poured into a Petri dish (86mm diameter) and placed in a fridge overnight to set into solid gel to represent the buccal mucosa surface. Mucin solution (2% w/v) was prepared by dissolving mucin powder from porcine stomach in a phosphate buffer (pH 6.8) and 0.5ml evenly spread on the surface of the set gelatine gel.
Using the TA analyser, the probe with film or wafer attached was lowered to make contact with the model buccal mucosa surface and was detached after the contact time of 60 sec with an applied force of 1.0N. Mucoadhesive strength was determined by the maximum adhesive force (Fmax) required to detach the sample from the model buccal surface, work of adhesion was determined by the area under the force-distance curve, while cohesiveness represents the distance the films/wafers travelled till they detached from the model buccal surface. Texture Exponent 32 ® software was used in collecting and processing the data from the texture analyser.
HPLC analysis
NIC was analysed by HPLC using an Agilent 1200 HPLC instrument (Agilent Technologies, Cheshire, UK) with an auto sampler. The stationary phase used was a C-18 reverse-phase column, 4.6 x 250mm (Phenomenex HPLC column, Cheshire, UK). Trimethylamine, methanol and sodium acetate (88:12:0.5 v/v) were used as mobile phase pH adjusted to 4.2 using glacial acetic acid, at a flow rate of 1ml/min and UV detection at 259nm 15 . The retention time of NIC was detected at approximately 4.5 min. Calibration curve was plotted using standards with NIC concentration ranging from 40µg/ml to 400µg/ml (R 2 =0.9994).
Drug content (% loading and recovery)
The content of NIC in DL films and wafers was assayed, by accurately weighing both DL films and wafers and dissolving in 10ml of distilled water. The resulting film/wafer solution was collected into a syringe, filtered through a 0.45µm cellulose acetate membrane, transferred into HPLC vials and placed in HPLC sample chamber and analysed as described above (n=3).
In vitro drug dissolution
In vitro drug dissolution of DL wafers was performed with the help of a Franz-diffusion cell apparatus. The receptor compartment was filled with 8ml of phosphate buffer (pH 6.8) with a mesh on the receptor surface. The donor and receptor compartments were sealed with paraffin, to limit evaporation and held together by a pinch clamp. The system was placed on a water bath at 37°C with magnetic stirring at approximately 200rpm. The wafer samples were weighed and placed on the mesh between the donor and receptor compartments. At predetermined time intervals, 0.5ml aliquots of the dissolution media were withdrawn using a 1ml syringe, filtered through a 0.45µm cellulose acetate membrane, transferred into HPLC vials and analysed using HPLC. Each aliquot withdrawn at each time point, was replaced with fresh buffer solution, in order to maintain a constant volume of dissolution media. The percentage drug released from wafers was calculated and plotted against time (n=3).
Statistical analysis
Statistical analysis was performed using student t-test and / or one-way ANOVA to compare the results. The results were expressed as mean ± standard deviation and significant differences were determined at a level of p < 0.05.
Results
Formulation development Films
BK unplasticised HPMC film with no SA was highly brittle and therefore was difficult to remove from the Petri dish. As a result, GLY was added to the polymeric solutions to reduce brittleness and increase flexibility of the final films. The optimum concentration of GLY (2% w/v) present in the polymeric solutions for the BK HPMC film was selected based on texture analysis and SEM analysis.
Polymeric solutions of plasticised composite HPMC-SA films were easy to pour and were easy to remove from the Petri dish after oven drying. DL HPMC-SA films were much easier to remove from Petri dishes than BK HPMC-SA film. All HPMC-SA films were transparent but as concentration of SA increased, the film showed a light yellowish colour imparted by pure SA powder.
Wafers
HPMC wafers formulated by lyophilisation were easily removed from well plates, easy to handle and were intact, therefore there was no need to use plasticiser to enhance their physical and handling properties unlike the films. 
Texture analysis (TA)
Tensile properties of films
Mechanical properties of wafer (hardness)
Texture analysis was used to determine the resistance to compressive deformation (hardness) of the BK and DL HPMC-SA wafers. 
Wafers pore analysis
Wafer pore analysis was performed to complement the SEM analysis with the aim of semiquantitatively analysing the porosity of the wafers with different SA content in composite HPMC-SA formulations. The result of the porosity (%) ranged from 61 -74%, with the porosity increasing as SA content increased within the formulations. The porosity results however, confirms the less collapsed pores of wafers containing higher amounts of SA (SA 0.50 and 0.75).
XRD analysis
Figure 6(a) shows XRD transmission diffractograms of pure polymers (SA and HPMC) and mylar (used in pure powder preparation to hold the powder and prevent it from spilling). The results show the amorphous nature of SA with a broad peak at 2θ 14° and 22°, whilst HPMC also showed a broad peak at 2θ 20°. Figures 6(b) and 6(c) shows the XRD transmission diffractograms of BLK HPMC-SA and DL HPMC-SA films respectively. Both BK and DL HPMC-SA films and wafers exhibited an amorphous nature, with a broad peak around 2θ of 20°. However, the wafers also showed a small crystalline shoulder peak at 2θ of 23°. Given that this peak was not present in the films, it could be attributed to false peak detection arising from compression of the wafers which causes the leafy networks to be piled up on top of each other and detected as a false crystalline peak. However, this might require further investigation to rule out possibility of trace amounts of other material naturally present in one of the polymers.
Attenuated total reflection Fourier transform infrared spectroscopy (ATR-FTIR) analysis.
The major peaks from the ATR-FTIR spectra of pure powders, BK and DL HPMC-SA composite films and BK and DL HPMC-SA composite wafers are summarised in Figure 7 .
The characteristic peaks of SA, HPMC and GLY can be seen in Figure 7a . BK HPMC-SA composite films (Figure 7b) showed a shift to lower wavenumbers for OH stretching vibration as SA concentration increased except for BK SA 0.25 film, which showed a much higher OH stretching vibration band at 3370cm -1 . Hydrogen bonding in COO groups was also observed at higher SA concentration as evidenced by shifting to lower wavenumber from 1647 cm -1 to 1607 cm -1 for COO-asymmetric stretching and the disappearance of the peak for COO-symmetric stretching (composite BK HPMC: SA 0.50 films) at 1455 cm -1 present from the spectra of the composite BK HPMC: SA 0.75 films. The shift in C-CH3 bending was a result of GLY present in the HPMC-SA composite films. DL HPMC-SA films (Figure 7c) also showed a shift in OH stretching vibration to lower bands as SA concentration increased except for SA 0.50 film at 3340cm -1 which showed similar OH vibration with HPMC only film (i.e. SA 0.00).
Characteristic peaks for BK HPMC-SA composite wafers are summarised in Figure 7d . 
DSC analysis
DSC analysis was used to investigate the thermal properties of pure polymer powders, and the HPMC-SA composite films and wafers. HPMC-SA wafers showed maximum peak temperature between 60-72°C.
Swelling studies
Figures 9(a) and (b) show changes in swelling index of HPMC-SA films and wafers respectively with time. The swelling profile in Figure 9 (a) demonstrate a decrease in swelling index (%) with increase in SA content within HPMC-SA films, while the swelling profile in Figure 9 (b) demonstrate an increase in swelling index as SA increased for HPMC-SA wafers.
However, there was no statistically significant difference between the different film formulations (p = 0.726, one-way ANOVA) as well as between the wafers (p=0.355, oneway ANOVA). In addition, it can also be observed that while HPMC-SA films showed a gradual increase in swelling index (%) with time, HPMC-SA wafers showed a more rapid increase in swelling index (%) within a short time (2 mins) and then remained constant over the duration of the study.
Mucoadhesion studies
Figures 10 and 11 show the mucoadhesion profiles of BK and DL HPMC-SA films, and BK and DL HPMC-SA wafers respectively obtained from the TA curves during the analysis. 
Drug content (% loading / recovery)
The films showed a very low percentage of NIC with a maximum assayed content below 
In vitro drug dissolution
Due to the very low drug contents observed in all the films, DL HPMC-SA films were discontinued from further analysis. Figure 12 shows the dissolution profiles of DL HPMC-SA composite wafers. DL HPMC-SA composite wafers with the highest SA concentration (SA 0.75) showed the highest % cumulative drug release within 4 hrs as compared to other composite wafers with a significant difference (p=0.041, one-way ANOVA). The DL HPMC-SA composite wafers with the highest SA concentration released 92 ± 8% within the first 30 mins and up to a 100% in 4 hrs in comparison with other HPMC-SA composite wafers, which released less than 60% within 4 hrs.
Discussion
The polymers used to prepare the composite films and wafers, were selected based on their mucoadhesive characteristics as well as their classification as GRAS. HPMC was selected based on its ability to control release of drug incorporated within a delivery system as well as its accessibility in regards to low cost of production [24] . SA on the hand was considered based on its mucoadhesive property as an anionic material, usually considered a better mucoadhesive polymer than non-ionic polymers such as HPMC [25, 26] . SA was also considered based on its ability to form ionic interactions by interacting with the positive charge of protonated NIC [15].
The dosage forms (i.e. solvent cast films and freeze-dried wafers) compared to determine drug loading efficiency due to the challenges posed by incorporating NIC, which is volatile into drug delivery systems. The consideration of plasticiser in films was the result of the brittleness and poor handling of unplasticised films during preliminary formulation development. The incorporation of plasticiser aids in increasing the free volume between the polymer chains (HPMC and SA) with the ability to slip past each other, resulting in more flexible films which are easy to handle [27] . The effect of plasticiser therefore decreased brittleness (tensile strength) and stiffness (elastic modulus) but increased elasticity (percentage elongation at break) in HPMC films. However, excess of plasticiser could result in higher free volume between polymers that are highly slippery and difficult to handle (very sticky) as shown in mechanical properties and SEM images of BK HPMC films obtained from polymeric solution with GLY above 2% w/v. Therefore a balance between flexibility and toughness with an optimum elongation ideally between 30-50% is desirable [28] .
Optimised concentration of GLY at 2% w/v within the original polymeric solution met the criteria of an ideal film based on its elongation and was therefore the concentration of choice in DL films.
Wafers on the other hand did not show any difficulty in handling, due to the ability to control the thermal events during freeze drying cycle. The thermal programme used was essential in achieving a cake structure that can be easy to handle by improving the freezing, primary and secondary drying stages. Using a controlled freezing process incorporating an annealing step, the ice crystal size and distribution was improved leading to better spongelike pores preceding sublimation via primary and secondary drying [29] .
HPMC and SA composite formulations formed a network polymeric matrix with a non-ionic interaction between the polymers. SA showed no plasticising effect on HPMC-SA composite films as the brittleness (tensile strength) of the films remained constant. However, NIC in the formulation increased the elongation but decreased the stiffness of the film while interacting with SA via ionic and hydrogen bonding. By this interaction, NIC increases the free volume between SA and HPMC thereby exhibiting a plasticising effect on the film.
Handling of wafers is important during application and therefore optimised mechanical property is necessary. The resistance of wafers against compression deformation data permits the assessment of the reliability of wafer structure [30] . The increase in hardness of BK wafers at higher SA concentration was possible due to hydrogen bonding existing between the COO -group of SA and the OH group of HPMC, which may interrupt the polymeric matrix of HPMC and hence increased the resistance to compression forces but was limited for wafers with lower SA concentration (SA 0.25). Wafers loaded with NIC decreased in resistance to deformation, which can be attributed to the NIC causing a slight increase in free volume between HPMC and SA polymeric chains in the composite wafers as observed in HPMC-SA composite films where there was increase in elasticity and decrease in stiffness.
Hydration and swelling behaviour of a dosage form can influence the drug dissolution profile, since diffusion, swelling and erosion are the mechanisms by which drug release is controlled [24] . wafers showed a porous in internal morphology, higher mucoadhesion, swelling index and drug loading capacity than HPMC-SA composite films. SA polymer used in the development of HPMC-SA composite wafers modified and improved properties of HPMC at optimum SA concentration and hence can be utilised as a drug delivery system for NRT. The polymeric composite system comprising HPMC and SA can be effective in enhancing the functional properties of buccal NRT to achieve desired optimum characteristics as an improvement over the currently used chewing gum which is difficult to control in terms of drug release.
Conflict of interest
The authors report no conflict of interest 
Figure 12
In vitro drug release profiles of DL HPMC-SA composite wafers. 
